NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Incidence and trends of HPV-related cancers in the United States

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

ASCO 2021: Renal cancer roundup

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

European Cancer Organisation - Time to Act

European Cancer Organisation: Time To Act

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems